Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Interferon Alpha-2a Biosimilar Market Research Report 2025

Global Interferon Alpha-2a Biosimilar Market Research Report 2025

Industry: Pharma & Healthcare

Published Date: 2025-02-09

Pages: 81 Pages

Report ld: 3469663

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Interferon Alpha-2a Biosimilar Market Size(US$)

CAGR 2025-2031

-5%

Market Size,2031

USD 111

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 151 million

Market Forecast in 2031(Value)

US$ 111 million

CAGR

-5%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Interferon Alpha-2a Biosimilar was valued at US$ 167 million in the year 2024 and is projected to reach a revised size of US$ 111 million by 2031, growing at a CAGR of -5.0% during the forecast period.

Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.

The Interferon Alpha-2a Biosimilar market is driven by the increasing global demand for cost-effective therapeutic options for diseases like hepatitis C, hepatitis B, and certain cancers. Biosimilars provide a more affordable alternative to branded biologics, enabling broader patient access, especially in developing regions. Additionally, the expiration of patents for key branded interferon products has opened the market for biosimilar entry. Government initiatives to promote biosimilar adoption, coupled with advancements in biomanufacturing technologies, further support market growth by reducing production costs and improving product availability.

A major challenge in the Interferon Alpha-2a Biosimilar market is the complex regulatory landscape, which requires rigorous clinical trials to prove biosimilarity and safety, increasing development costs and time. Market penetration is also hindered by physician and patient skepticism regarding the efficacy and safety of biosimilars compared to branded counterparts. Furthermore, the dominance of established biologics and intense competition from alternative therapies, such as direct-acting antivirals (DAAs) for hepatitis, limit market growth. Pricing pressures and reimbursement challenges in several markets further complicate the adoption of biosimilars.

Global Interferon Alpha-2a Biosimilar key players include Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, etc. Global top five manufacturers hold a share about 95%. Europe is the largest market, with a share about 60%, followed by Asia, with a share about 10 percent. In terms of product, Ordinary Type is the largest segment, with a share about 70%. And in terms of application, the largest application is Hepatitis C, followed by Hepatitis B, etc.

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Interferon Alpha-2a Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Interferon Alpha-2a Biosimilar.

The Interferon Alpha-2a Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Interferon Alpha-2a Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Interferon Alpha-2a Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

Roche

Biosidus

Zydus Cadila

Nanogen

Amega Biotech

Echo Therapeutics

Cheplapharm

SUMMIT SD

Changchun Institute of Biological Products

3 SBIO

Segment by Type

Long-lasting Type

Ordinary Type

Segment by Application

Hepatitis C

Hepatitis B

Others

Consumption by Region

North America

U.S.

Canada

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Europe

Germany

France

U.K.

Italy

Russia

Latin America

Mexico

Brazil

Argentina

Middle East and Africa

Turkey

Saudi Arabia

U.A.E

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Interferon Alpha-2a Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Interferon Alpha-2a Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Interferon Alpha-2a Biosimilar Market Overview

1.1 Product Definition

1.2 Interferon Alpha-2a Biosimilar by Type

1.2.1 Global Interferon Alpha-2a Biosimilar Market Value Comparison by Type (2024 VS 2031)

1.2.2 Long-lasting Type

1.2.3 Ordinary Type

1.3 Interferon Alpha-2a Biosimilar by Application

1.3.1 Global Interferon Alpha-2a Biosimilar Market Value by Application (2024 VS 2031)

1.3.2 Hepatitis C

1.3.3 Hepatitis B

1.3.4 Others

1.4 Global Interferon Alpha-2a Biosimilar Market Size Estimates and Forecasts

1.4.1 Global Interferon Alpha-2a Biosimilar Revenue 2020-2031

1.4.2 Global Interferon Alpha-2a Biosimilar Sales 2020-2031

1.4.3 Global Interferon Alpha-2a Biosimilar Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Interferon Alpha-2a Biosimilar Market Competition by Manufacturers

2.1 Global Interferon Alpha-2a Biosimilar Sales Market Share by Manufacturers (2020-2025)

2.2 Global Interferon Alpha-2a Biosimilar Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Interferon Alpha-2a Biosimilar Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Interferon Alpha-2a Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Interferon Alpha-2a Biosimilar, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Interferon Alpha-2a Biosimilar, Product Type & Application

2.7 Global Key Manufacturers of Interferon Alpha-2a Biosimilar, Date of Enter into This Industry

2.8 Global Interferon Alpha-2a Biosimilar Market Competitive Situation and Trends

2.8.1 Global Interferon Alpha-2a Biosimilar Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Interferon Alpha-2a Biosimilar Players Market Share by Revenue

2.8.3 Global Interferon Alpha-2a Biosimilar Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Interferon Alpha-2a Biosimilar Market Scenario by Region

3.1 Global Interferon Alpha-2a Biosimilar Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Interferon Alpha-2a Biosimilar Sales by Region: 2020-2031

3.2.1 Global Interferon Alpha-2a Biosimilar Sales by Region: 2020-2025

3.2.2 Global Interferon Alpha-2a Biosimilar Sales by Region: 2026-2031

3.3 Global Interferon Alpha-2a Biosimilar Revenue by Region: 2020-2031

3.3.1 Global Interferon Alpha-2a Biosimilar Revenue by Region: 2020-2025

3.3.2 Global Interferon Alpha-2a Biosimilar Revenue by Region: 2026-2031

3.4 North America Interferon Alpha-2a Biosimilar Market Facts & Figures by Country

3.4.1 North America Interferon Alpha-2a Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Interferon Alpha-2a Biosimilar Sales by Country (2020-2031)

3.4.3 North America Interferon Alpha-2a Biosimilar Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Interferon Alpha-2a Biosimilar Market Facts & Figures by Country

3.5.1 Europe Interferon Alpha-2a Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Interferon Alpha-2a Biosimilar Sales by Country (2020-2031)

3.5.3 Europe Interferon Alpha-2a Biosimilar Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Interferon Alpha-2a Biosimilar Market Facts & Figures by Region

3.6.1 Asia Pacific Interferon Alpha-2a Biosimilar Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Interferon Alpha-2a Biosimilar Sales by Region (2020-2031)

3.6.3 Asia Pacific Interferon Alpha-2a Biosimilar Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Interferon Alpha-2a Biosimilar Market Facts & Figures by Country

3.7.1 Latin America Interferon Alpha-2a Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Interferon Alpha-2a Biosimilar Sales by Country (2020-2031)

3.7.3 Latin America Interferon Alpha-2a Biosimilar Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Interferon Alpha-2a Biosimilar Market Facts & Figures by Country

3.8.1 Middle East and Africa Interferon Alpha-2a Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Interferon Alpha-2a Biosimilar Sales by Country (2020-2031)

3.8.3 Middle East and Africa Interferon Alpha-2a Biosimilar Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Interferon Alpha-2a Biosimilar Sales by Type (2020-2031)

4.1.1 Global Interferon Alpha-2a Biosimilar Sales by Type (2020-2025)

4.1.2 Global Interferon Alpha-2a Biosimilar Sales by Type (2026-2031)

4.1.3 Global Interferon Alpha-2a Biosimilar Sales Market Share by Type (2020-2031)

4.2 Global Interferon Alpha-2a Biosimilar Revenue by Type (2020-2031)

4.2.1 Global Interferon Alpha-2a Biosimilar Revenue by Type (2020-2025)

4.2.2 Global Interferon Alpha-2a Biosimilar Revenue by Type (2026-2031)

4.2.3 Global Interferon Alpha-2a Biosimilar Revenue Market Share by Type (2020-2031)

4.3 Global Interferon Alpha-2a Biosimilar Price by Type (2020-2031)

5 Segment by Application

5.1 Global Interferon Alpha-2a Biosimilar Sales by Application (2020-2031)

5.1.1 Global Interferon Alpha-2a Biosimilar Sales by Application (2020-2025)

5.1.2 Global Interferon Alpha-2a Biosimilar Sales by Application (2026-2031)

5.1.3 Global Interferon Alpha-2a Biosimilar Sales Market Share by Application (2020-2031)

5.2 Global Interferon Alpha-2a Biosimilar Revenue by Application (2020-2031)

5.2.1 Global Interferon Alpha-2a Biosimilar Revenue by Application (2020-2025)

5.2.2 Global Interferon Alpha-2a Biosimilar Revenue by Application (2026-2031)

5.2.3 Global Interferon Alpha-2a Biosimilar Revenue Market Share by Application (2020-2031)

5.3 Global Interferon Alpha-2a Biosimilar Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Roche Interferon Alpha-2a Biosimilar Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Biosidus

6.2.1 Biosidus Company Information

6.2.2 Biosidus Description and Business Overview

6.2.3 Biosidus Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Biosidus Interferon Alpha-2a Biosimilar Product Portfolio

6.2.5 Biosidus Recent Developments/Updates

6.3 Zydus Cadila

6.3.1 Zydus Cadila Company Information

6.3.2 Zydus Cadila Description and Business Overview

6.3.3 Zydus Cadila Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Zydus Cadila Interferon Alpha-2a Biosimilar Product Portfolio

6.3.5 Zydus Cadila Recent Developments/Updates

6.4 Nanogen

6.4.1 Nanogen Company Information

6.4.2 Nanogen Description and Business Overview

6.4.3 Nanogen Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Nanogen Interferon Alpha-2a Biosimilar Product Portfolio

6.4.5 Nanogen Recent Developments/Updates

6.5 Amega Biotech

6.5.1 Amega Biotech Company Information

6.5.2 Amega Biotech Description and Business Overview

6.5.3 Amega Biotech Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Amega Biotech Interferon Alpha-2a Biosimilar Product Portfolio

6.5.5 Amega Biotech Recent Developments/Updates

6.6 Echo Therapeutics

6.6.1 Echo Therapeutics Company Information

6.6.2 Echo Therapeutics Description and Business Overview

6.6.3 Echo Therapeutics Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Echo Therapeutics Interferon Alpha-2a Biosimilar Product Portfolio

6.6.5 Echo Therapeutics Recent Developments/Updates

6.7 Cheplapharm

6.7.1 Cheplapharm Company Information

6.7.2 Cheplapharm Description and Business Overview

6.7.3 Cheplapharm Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Cheplapharm Interferon Alpha-2a Biosimilar Product Portfolio

6.7.5 Cheplapharm Recent Developments/Updates

6.8 SUMMIT SD

6.8.1 SUMMIT SD Company Information

6.8.2 SUMMIT SD Description and Business Overview

6.8.3 SUMMIT SD Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.8.4 SUMMIT SD Interferon Alpha-2a Biosimilar Product Portfolio

6.8.5 SUMMIT SD Recent Developments/Updates

6.9 Changchun Institute of Biological Products

6.9.1 Changchun Institute of Biological Products Company Information

6.9.2 Changchun Institute of Biological Products Description and Business Overview

6.9.3 Changchun Institute of Biological Products Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Changchun Institute of Biological Products Interferon Alpha-2a Biosimilar Product Portfolio

6.9.5 Changchun Institute of Biological Products Recent Developments/Updates

6.10 3 SBIO

6.10.1 3 SBIO Company Information

6.10.2 3 SBIO Description and Business Overview

6.10.3 3 SBIO Interferon Alpha-2a Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.10.4 3 SBIO Interferon Alpha-2a Biosimilar Product Portfolio

6.10.5 3 SBIO Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Interferon Alpha-2a Biosimilar Industry Chain Analysis

7.2 Interferon Alpha-2a Biosimilar Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Interferon Alpha-2a Biosimilar Production Mode & Process Analysis

7.4 Interferon Alpha-2a Biosimilar Sales and Marketing

7.4.1 Interferon Alpha-2a Biosimilar Sales Channels

7.4.2 Interferon Alpha-2a Biosimilar Distributors

7.5 Interferon Alpha-2a Biosimilar Customer Analysis

8 Interferon Alpha-2a Biosimilar Market Dynamics

8.1 Interferon Alpha-2a Biosimilar Industry Trends

8.2 Interferon Alpha-2a Biosimilar Market Drivers

8.3 Interferon Alpha-2a Biosimilar Market Challenges

8.4 Interferon Alpha-2a Biosimilar Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Interferon Alpha-2a Biosimilar Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Interferon Alpha-2a Biosimilar Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Interferon Alpha-2a Biosimilar Market Competitive Situation by Manufacturers in 2024

Table 4. Global Interferon Alpha-2a Biosimilar Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Interferon Alpha-2a Biosimilar Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Interferon Alpha-2a Biosimilar Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Interferon Alpha-2a Biosimilar Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Interferon Alpha-2a Biosimilar Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Interferon Alpha-2a Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Interferon Alpha-2a Biosimilar, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Interferon Alpha-2a Biosimilar, Product Type & Application

Table 12. Global Key Manufacturers of Interferon Alpha-2a Biosimilar, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Interferon Alpha-2a Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Interferon Alpha-2a Biosimilar as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Interferon Alpha-2a Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Interferon Alpha-2a Biosimilar Sales by Region (2020-2025) & (K Units)

Table 18. Global Interferon Alpha-2a Biosimilar Sales Market Share by Region (2020-2025)

Table 19. Global Interferon Alpha-2a Biosimilar Sales by Region (2026-2031) & (K Units)

Table 20. Global Interferon Alpha-2a Biosimilar Sales Market Share by Region (2026-2031)

Table 21. Global Interferon Alpha-2a Biosimilar Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Interferon Alpha-2a Biosimilar Revenue Market Share by Region (2020-2025)

Table 23. Global Interferon Alpha-2a Biosimilar Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Interferon Alpha-2a Biosimilar Revenue Market Share by Region (2026-2031)

Table 25. North America Interferon Alpha-2a Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Interferon Alpha-2a Biosimilar Sales by Country (2020-2025) & (K Units)

Table 27. North America Interferon Alpha-2a Biosimilar Sales by Country (2026-2031) & (K Units)

Table 28. North America Interferon Alpha-2a Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Interferon Alpha-2a Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Interferon Alpha-2a Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Interferon Alpha-2a Biosimilar Sales by Country (2020-2025) & (K Units)

Table 32. Europe Interferon Alpha-2a Biosimilar Sales by Country (2026-2031) & (K Units)

Table 33. Europe Interferon Alpha-2a Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Interferon Alpha-2a Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Interferon Alpha-2a Biosimilar Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Interferon Alpha-2a Biosimilar Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Interferon Alpha-2a Biosimilar Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Interferon Alpha-2a Biosimilar Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Interferon Alpha-2a Biosimilar Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Interferon Alpha-2a Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Interferon Alpha-2a Biosimilar Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Interferon Alpha-2a Biosimilar Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Interferon Alpha-2a Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Interferon Alpha-2a Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Interferon Alpha-2a Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Interferon Alpha-2a Biosimilar Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Interferon Alpha-2a Biosimilar Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Interferon Alpha-2a Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Interferon Alpha-2a Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Interferon Alpha-2a Biosimilar Sales (K Units) by Type (2020-2025)

Table 51. Global Interferon Alpha-2a Biosimilar Sales (K Units) by Type (2026-2031)

Table 52. Global Interferon Alpha-2a Biosimilar Sales Market Share by Type (2020-2025)

Table 53. Global Interferon Alpha-2a Biosimilar Sales Market Share by Type (2026-2031)

Table 54. Global Interferon Alpha-2a Biosimilar Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Interferon Alpha-2a Biosimilar Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Interferon Alpha-2a Biosimilar Revenue Market Share by Type (2020-2025)

Table 57. Global Interferon Alpha-2a Biosimilar Revenue Market Share by Type (2026-2031)

Table 58. Global Interferon Alpha-2a Biosimilar Price (USD/Unit) by Type (2020-2025)

Table 59. Global Interferon Alpha-2a Biosimilar Price (USD/Unit) by Type (2026-2031)

Table 60. Global Interferon Alpha-2a Biosimilar Sales (K Units) by Application (2020-2025)

Table 61. Global Interferon Alpha-2a Biosimilar Sales (K Units) by Application (2026-2031)

Table 62. Global Interferon Alpha-2a Biosimilar Sales Market Share by Application (2020-2025)

Table 63. Global Interferon Alpha-2a Biosimilar Sales Market Share by Application (2026-2031)

Table 64. Global Interferon Alpha-2a Biosimilar Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Interferon Alpha-2a Biosimilar Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Interferon Alpha-2a Biosimilar Revenue Market Share by Application (2020-2025)

Table 67. Global Interferon Alpha-2a Biosimilar Revenue Market Share by Application (2026-2031)

Table 68. Global Interferon Alpha-2a Biosimilar Price (USD/Unit) by Application (2020-2025)

Table 69. Global Interferon Alpha-2a Biosimilar Price (USD/Unit) by Application (2026-2031)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Roche Interferon Alpha-2a Biosimilar Product

Table 74. Roche Recent Developments/Updates

Table 75. Biosidus Company Information

Table 76. Biosidus Description and Business Overview

Table 77. Biosidus Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Biosidus Interferon Alpha-2a Biosimilar Product

Table 79. Biosidus Recent Developments/Updates

Table 80. Zydus Cadila Company Information

Table 81. Zydus Cadila Description and Business Overview

Table 82. Zydus Cadila Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Zydus Cadila Interferon Alpha-2a Biosimilar Product

Table 84. Zydus Cadila Recent Developments/Updates

Table 85. Nanogen Company Information

Table 86. Nanogen Description and Business Overview

Table 87. Nanogen Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Nanogen Interferon Alpha-2a Biosimilar Product

Table 89. Nanogen Recent Developments/Updates

Table 90. Amega Biotech Company Information

Table 91. Amega Biotech Description and Business Overview

Table 92. Amega Biotech Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Amega Biotech Interferon Alpha-2a Biosimilar Product

Table 94. Amega Biotech Recent Developments/Updates

Table 95. Echo Therapeutics Company Information

Table 96. Echo Therapeutics Description and Business Overview

Table 97. Echo Therapeutics Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Echo Therapeutics Interferon Alpha-2a Biosimilar Product

Table 99. Echo Therapeutics Recent Developments/Updates

Table 100. Cheplapharm Company Information

Table 101. Cheplapharm Description and Business Overview

Table 102. Cheplapharm Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Cheplapharm Interferon Alpha-2a Biosimilar Product

Table 104. Cheplapharm Recent Developments/Updates

Table 105. SUMMIT SD Company Information

Table 106. SUMMIT SD Description and Business Overview

Table 107. SUMMIT SD Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. SUMMIT SD Interferon Alpha-2a Biosimilar Product

Table 109. SUMMIT SD Recent Developments/Updates

Table 110. Changchun Institute of Biological Products Company Information

Table 111. Changchun Institute of Biological Products Description and Business Overview

Table 112. Changchun Institute of Biological Products Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Changchun Institute of Biological Products Interferon Alpha-2a Biosimilar Product

Table 114. Changchun Institute of Biological Products Recent Developments/Updates

Table 115. 3 SBIO Company Information

Table 116. 3 SBIO Description and Business Overview

Table 117. 3 SBIO Interferon Alpha-2a Biosimilar Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. 3 SBIO Interferon Alpha-2a Biosimilar Product

Table 119. 3 SBIO Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Interferon Alpha-2a Biosimilar Distributors List

Table 123. Interferon Alpha-2a Biosimilar Customers List

Table 124. Interferon Alpha-2a Biosimilar Market Trends

Table 125. Interferon Alpha-2a Biosimilar Market Drivers

Table 126. Interferon Alpha-2a Biosimilar Market Challenges

Table 127. Interferon Alpha-2a Biosimilar Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Interferon Alpha-2a Biosimilar

Figure 2. Global Interferon Alpha-2a Biosimilar Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Interferon Alpha-2a Biosimilar Market Share by Type: 2024 & 2031

Figure 4. Long-lasting Type Product Picture

Figure 5. Ordinary Type Product Picture

Figure 6. Global Interferon Alpha-2a Biosimilar Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Interferon Alpha-2a Biosimilar Market Share by Application: 2024 & 2031

Figure 8. Hepatitis C

Figure 9. Hepatitis B

Figure 10. Others

Figure 11. Global Interferon Alpha-2a Biosimilar Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Interferon Alpha-2a Biosimilar Market Size (2020-2031) & (US$ Million)

Figure 13. Global Interferon Alpha-2a Biosimilar Sales (2020-2031) & (K Units)

Figure 14. Global Interferon Alpha-2a Biosimilar Average Price (USD/Unit) & (2020-2031)

Figure 15. Interferon Alpha-2a Biosimilar Report Years Considered

Figure 16. Interferon Alpha-2a Biosimilar Sales Share by Manufacturers in 2024

Figure 17. Global Interferon Alpha-2a Biosimilar Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Interferon Alpha-2a Biosimilar Players: Market Share by Revenue in Interferon Alpha-2a Biosimilar in 2024

Figure 19. Interferon Alpha-2a Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Interferon Alpha-2a Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Interferon Alpha-2a Biosimilar Sales Market Share by Country (2020-2031)

Figure 22. North America Interferon Alpha-2a Biosimilar Revenue Market Share by Country (2020-2031)

Figure 23. U.S. Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Interferon Alpha-2a Biosimilar Sales Market Share by Country (2020-2031)

Figure 26. Europe Interferon Alpha-2a Biosimilar Revenue Market Share by Country (2020-2031)

Figure 27. Germany Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Interferon Alpha-2a Biosimilar Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Interferon Alpha-2a Biosimilar Revenue Market Share by Region (2020-2031)

Figure 34. China Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Taiwan Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Indonesia Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Thailand Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Malaysia Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Philippines Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Interferon Alpha-2a Biosimilar Sales Market Share by Country (2020-2031)

Figure 45. Latin America Interferon Alpha-2a Biosimilar Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Interferon Alpha-2a Biosimilar Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Interferon Alpha-2a Biosimilar Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. U.A.E Interferon Alpha-2a Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Interferon Alpha-2a Biosimilar by Type (2020-2031)

Figure 55. Global Revenue Market Share of Interferon Alpha-2a Biosimilar by Type (2020-2031)

Figure 56. Global Interferon Alpha-2a Biosimilar Price (USD/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Interferon Alpha-2a Biosimilar by Application (2020-2031)

Figure 58. Global Revenue Market Share of Interferon Alpha-2a Biosimilar by Application (2020-2031)

Figure 59. Global Interferon Alpha-2a Biosimilar Price (USD/Unit) by Application (2020-2031)

Figure 60. Interferon Alpha-2a Biosimilar Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, -5% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

What was the global market size of Interferon Alpha-2a Biosimilar in 2025? shouQi

What was the global market size of Interferon Alpha-2a Biosimilar in 2031? shouQi

Which companies rank high in the global Interferon Alpha-2a Biosimilar market? shouQi

What is the annual compound growth rate of the global Interferon Alpha-2a Biosimilar market size from 2025 to 2031? shouQi

Related Reports

Global Interferon Alpha-2a Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Interferon Alpha-2a Biosimilar market size was US$ 151 million in 2025 and is forecast to reach a readjusted size of US$ 106 million by 2032 with a CAGR of -5.0% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 78
USD 4250.00
(Single User License)
Global Interferon Alpha-2a Biosimilar Market Research Report 2026
The global Interferon Alpha-2a Biosimilar market was valued at US$ 151 million in 2025 and is anticipated to reach US$ 106 million by 2032, at a CAGR of -5.0% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 108
USD 2900.00
(Single User License)
Interferon Alpha-2a Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Interferon Alpha-2a Biosimilar was estimated to be worth US$ 151 million in 2025 and is projected to reach US$ 106 million, growing at a CAGR of -5.0% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 97
USD 3950.00
(Single User License)
Global Interferon Alpha-2a Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Interferon Alpha-2a Biosimilar market is projected to grow from US$ 167 million in 2024 to US$ 111 million by 2031, at a CAGR of -5.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 131
USD 4900.00
(Single User License)
Global Interferon Alpha-2a Biosimilar Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Interferon Alpha-2a Biosimilar was estimated to be worth US$ 167 million and is forecast to reach approximately US$ 111 million by 2031 with a CAGR of -5.0% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 137
USD 5900.00
(Single User License)
Global Interferon Alpha-2a Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Interferon Alpha-2a Biosimilar market size was US$ 167 million in 2024 and is forecast to a readjusted size of US$ 111 million by 2031 with a CAGR of -5.0% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 80
USD 4250.00
(Single User License)
Interferon Alpha-2a Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Interferon Alpha-2a Biosimilar was estimated to be worth US$ 167 million in 2024 and is forecast to a readjusted size of US$ 111 million by 2031 with a CAGR of -5.0% during the forecast period 2025-2031.
Published Date: 2025-02-09
Pages: 108
USD 3950.00
(Single User License)
Interferon Alpha-2a Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Interferon Alpha-2a Biosimilar was estimated to be worth US$ 167 million in 2024 and is forecast to a readjusted size of US$ 75 million by 2031 with a CAGR of -11.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 107
USD 3950.00
(Single User License)
Global Interferon Alpha-2a Biosimilar Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Published Date: 2024-04-17
Pages: 137
USD 5600.00
(Single User License)
Global Interferon Alpha-2a Biosimilar Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Published Date: 2024-04-16
Pages: 131
USD 5900.00
(Single User License)

Global Interferon Alpha-2a Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Interferon Alpha-2a Biosimilar market size was US$ 151 million in 2025 and is forecast to reach a readjusted size of US$ 106 million by 2032 with a CAGR of -5.0% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 78
USD 4250.00 (Single User License)
Global Interferon Alpha-2a Biosimilar Market Research Report 2026
The global Interferon Alpha-2a Biosimilar market was valued at US$ 151 million in 2025 and is anticipated to reach US$ 106 million by 2032, at a CAGR of -5.0% from 2026 to 2032.
Published: 2026-01-04
Pages: 108
USD 2900.00 (Single User License)
Interferon Alpha-2a Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Interferon Alpha-2a Biosimilar was estimated to be worth US$ 151 million in 2025 and is projected to reach US$ 106 million, growing at a CAGR of -5.0% from 2026 to 2032.
Published: 2026-01-04
Pages: 97
USD 3950.00 (Single User License)
Global Interferon Alpha-2a Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Interferon Alpha-2a Biosimilar market is projected to grow from US$ 167 million in 2024 to US$ 111 million by 2031, at a CAGR of -5.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 131
USD 4900.00 (Single User License)
Global Interferon Alpha-2a Biosimilar Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Interferon Alpha-2a Biosimilar was estimated to be worth US$ 167 million and is forecast to reach approximately US$ 111 million by 2031 with a CAGR of -5.0% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 137
USD 5900.00 (Single User License)
Global Interferon Alpha-2a Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Interferon Alpha-2a Biosimilar market size was US$ 167 million in 2024 and is forecast to a readjusted size of US$ 111 million by 2031 with a CAGR of -5.0% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 80
USD 4250.00 (Single User License)
Interferon Alpha-2a Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Interferon Alpha-2a Biosimilar was estimated to be worth US$ 167 million in 2024 and is forecast to a readjusted size of US$ 111 million by 2031 with a CAGR of -5.0% during the forecast period 2025-2031.
Published: 2025-02-09
Pages: 108
USD 3950.00 (Single User License)
Interferon Alpha-2a Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Interferon Alpha-2a Biosimilar was estimated to be worth US$ 167 million in 2024 and is forecast to a readjusted size of US$ 75 million by 2031 with a CAGR of -11.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 107
USD 3950.00 (Single User License)
Global Interferon Alpha-2a Biosimilar Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Published: 2024-04-17
Pages: 137
USD 5600.00 (Single User License)
Global Interferon Alpha-2a Biosimilar Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Published: 2024-04-16
Pages: 131
USD 5900.00 (Single User License)